Maple PT-141, also known as bremelanotide, is a synthetic cyclic heptapeptide that acts as a non-selective melanocortin receptor agonist with primary affinity for the MC3R and MC4R subtypes. Originally derived from the superpotent melanocortin analog Melanotan II, PT-141 has become one of the most studied peptides in melanocortin signaling research due to its unique central mechanism of action and its ability to cross the blood-brain barrier.
Unlike many peptides in the research pipeline that operate through peripheral pathways, PT-141 engages hypothalamic and limbic circuits directly, making it a valuable pharmacological tool for investigating the intersection of melanocortin signaling, dopaminergic modulation, and autonomic regulation. This article reviews the structural chemistry, receptor pharmacology, and preclinical evidence surrounding PT-141 research, with a focus on the mechanistic data that makes this peptide relevant to ongoing investigations in neuroscience and endocrinology.
For research purposes only. Not for human consumption. Not for diagnostic or therapeutic use.
Chemical Structure and Development History
PT-141 carries the systematic designation Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH. Its molecular formula is C50H68N14O10, and its molecular weight is 1025.18 g/mol. The peptide is cyclized through a lactam bridge between the aspartic acid and lysine residues, a structural feature that confers significant metabolic stability compared to linear melanocortin analogs.
The development lineage of PT-141 traces back to foundational work on melanocortin peptides at the University of Arizona during the 1980s and 1990s. Researchers led by Victor Hruby and Mac Hadley developed Melanotan II as a synthetic analog of alpha-melanocyte-stimulating hormone (alpha-MSH). During preclinical and early-phase investigations of Melanotan II, researchers observed that the compound produced pronounced central nervous system effects beyond its expected melanogenic activity. PT-141 was subsequently developed as a metabolite and standalone research compound to isolate these central effects from the broader melanocortin activity profile of its parent molecule.
The key structural modification that distinguishes PT-141 from naturally occurring melanocortins is the incorporation of D-phenylalanine at position 7 and norleucine at position 4. These substitutions enhance receptor binding affinity while simultaneously increasing resistance to enzymatic degradation by serum peptidases. The cyclic lactam bridge further restricts conformational flexibility, locking the peptide into a bioactive configuration that favors melanocortin receptor engagement.
Melanocortin Receptor Pharmacology
The melanocortin receptor system comprises five G protein-coupled receptor subtypes, designated MC1R through MC5R. Each subtype exhibits distinct tissue distribution patterns and downstream signaling characteristics. PT-141 demonstrates agonist activity at MC1R, MC3R, MC4R, and MC5R, with negligible affinity for MC2R (the ACTH receptor). However, the pharmacologically relevant activity of PT-141 in preclinical research concentrates primarily at MC3R and MC4R, both of which are densely expressed in hypothalamic nuclei and limbic structures.
MC4R is the most extensively characterized target of PT-141 in preclinical literature. When PT-141 binds MC4R, the receptor couples to both Gs and Gq alpha subunits, initiating parallel signaling cascades. The Gs pathway activates adenylyl cyclase, increasing intracellular cyclic AMP (cAMP) and engaging protein kinase A (PKA) dependent phosphorylation events. The Gq pathway activates phospholipase C (PLC), generating inositol trisphosphate (IP3) and diacylglycerol (DAG), which in turn elevate intracellular calcium and activate protein kinase C (PKC). Both pathways converge on ERK/MAPK signaling cascades in neuronal populations, a downstream integration point that has been linked to changes in synaptic plasticity and gene expression in relevant brain regions.
MC3R pharmacology is less completely characterized but has attracted increasing research attention. In contrast to MC4R, which appears to mediate acute behavioral responses in animal model studies, MC3R participates in mesolimbic dopamine regulation and demonstrates sex-dependent features in some preclinical paradigms. Research published by Girardet and Butler (2014) established that MC3R activity in ventral tegmental area (VTA) to nucleus accumbens (NAc) circuits modulates phasic dopamine signaling, a finding that positions MC3R as a potential mediator of motivational and reward-related processes that intersect with melanocortin signaling.
Central Nervous System Penetration and Distribution
One of the properties that distinguishes PT-141 from many research peptides is its demonstrated ability to cross the blood-brain barrier (BBB). This characteristic is functionally critical because the receptor targets most relevant to PT-141’s observed preclinical effects, specifically MC3R and MC4R in the hypothalamus and limbic system, are centrally located. Research by Molinoff and colleagues (2003) established that subcutaneous administration of PT-141 produces measurable changes in central melanocortin signaling, confirming functional BBB penetration at pharmacologically relevant concentrations.
Within the central nervous system, the anatomical regions most densely implicated in PT-141’s mechanism include the medial preoptic area (MPOA) and the paraventricular nucleus (PVN) of the hypothalamus. These regions are well-established in neuroscience literature as integration centers for autonomic output, neuroendocrine regulation, and behavioral circuitry. The MPOA receives convergent input from olfactory, limbic, and cortical pathways, while the PVN serves as a major output node connecting hypothalamic processing to brainstem autonomic centers and the posterior pituitary.
Preclinical tracing studies have demonstrated that PT-141 activates neuronal populations in these regions as measured by c-Fos expression, a marker of recent neuronal activity. The pattern of c-Fos induction following PT-141 administration overlaps substantially with the distribution of MC4R-expressing neurons identified through in situ hybridization, providing converging evidence that the observed central effects are mediated through direct melanocortin receptor engagement rather than indirect or off-target pathways.
Interaction with Dopaminergic Pathways
A significant body of preclinical evidence indicates that melanocortin signaling through MC3R and MC4R intersects with dopaminergic neurotransmission in regions relevant to motivation and arousal. This intersection has made PT-141 a useful pharmacological probe for studying how neuropeptide systems modulate catecholamine signaling in the mesolimbic and hypothalamic circuits.
In rodent model research, PT-141 administration increases dopamine release in the MPOA, as measured by in vivo microdialysis. This dopamine elevation is temporally correlated with changes in behavioral output in standardized assays, and it can be attenuated by pretreatment with selective MC4R antagonists, confirming the melanocortin dependence of the dopaminergic response. Importantly, the mechanism is distinct from direct dopamine receptor agonism. PT-141 does not bind dopamine receptors; instead, it appears to activate melanocortin-responsive neurons that project to or modulate dopaminergic cell groups.
This indirect modulatory relationship has implications for understanding how peptidergic systems shape monoamine signaling more broadly. Research on the melanocortin-dopamine axis has been cited as a model for studying neuropeptide-monoamine interactions in other contexts, including investigations into neuropeptide signaling compounds like Semax that also modulate catecholamine systems through indirect central mechanisms.
Relationship to Melanotan Peptides
PT-141’s developmental origin as a metabolite of Melanotan II places it within a broader family of melanocortin analogs that share structural features but differ in receptor selectivity and tissue distribution. Understanding these relationships is important for researchers working with melanocortin compounds, as the overlapping but non-identical pharmacological profiles create opportunities for comparative studies.
Melanotan I (afamelanotide) is a linear analog of alpha-MSH with preferential activity at MC1R, the receptor subtype primarily responsible for melanogenesis in dermal melanocytes. Melanotan II retains MC1R activity but adds significant MC3R and MC4R engagement, producing both peripheral melanogenic effects and central nervous system activity. PT-141, as a truncated cyclic derivative, preserves the MC3R/MC4R activity while reducing (though not eliminating) MC1R engagement, effectively concentrating the pharmacological profile on central targets.
For researchers conducting comparative studies across melanocortin analogs, the structural and pharmacological differences between these compounds provide a toolkit for dissecting receptor-specific contributions to observed outcomes. Using PT-141 alongside Melanotan I and Melanotan II in parallel experimental designs allows investigators to attribute effects to specific receptor subtypes based on the known selectivity profiles of each compound.
Preclinical Evidence in Neuroprotection Research
Beyond its primary use as a tool compound in melanocortin signaling research, PT-141 and related MC4R agonists have generated preliminary interest in neuroprotection paradigms. The rationale for this line of investigation stems from the broader observation that melanocortin signaling modulates neuroinflammatory pathways through MC4R-dependent mechanisms.
In animal model studies of cerebral ischemia, MC4R activation has been associated with reduced expression of pro-inflammatory cytokines including TNF-alpha and IL-1beta in perilesional tissue. These anti-inflammatory effects appear to be mediated through suppression of NF-kB signaling in microglial populations, a pathway that MC4R engagement can influence through cAMP-dependent mechanisms. While much of this neuroprotection literature has used selective MC4R agonists rather than PT-141 specifically, the shared receptor target suggests that PT-141’s pharmacological profile may encompass similar downstream signaling events.
Research into melanocortin-mediated neuroprotection connects to broader investigations into peptides that modulate central inflammatory and trophic pathways. Compounds such as Selank and Semax, which act through distinct receptor systems but share the property of central nervous system penetration and neuromodulatory activity, represent complementary tools for researchers investigating neuroprotective mechanisms across multiple signaling axes.
Autonomic and Neuroendocrine Effects in Preclinical Models
PT-141’s activation of hypothalamic melanocortin circuits produces measurable changes in autonomic output that have been documented across multiple preclinical studies. MC4R-expressing neurons in the PVN project to brainstem autonomic centers including the nucleus tractus solitarius (NTS) and the rostral ventrolateral medulla (RVLM), providing an anatomical substrate for melanocortin-mediated modulation of cardiovascular, respiratory, and other autonomic parameters.
In rodent models, PT-141 administration produces transient increases in mean arterial pressure and heart rate, effects that are blocked by central MC4R antagonism but not by peripheral adrenergic blockade alone. This pattern indicates that the cardiovascular effects originate from central melanocortin activation rather than direct peripheral vascular action, consistent with PT-141’s established mechanism as a centrally acting compound. These autonomic effects have been characterized across multiple dose ranges and administration routes in preclinical pharmacology studies, providing researchers with well-documented dose-response relationships for experimental design purposes.
Neuroendocrine effects documented in preclinical settings include modulation of oxytocin release from the posterior pituitary, a finding consistent with the known projections from MC4R-positive PVN neurons to the neurohypophysis. The oxytocin connection is particularly noteworthy because it suggests a mechanism by which melanocortin signaling could influence social and affiliative behaviors through a well-characterized neuropeptide intermediary, opening potential avenues for research into peptide-peptide signaling interactions.
Stability, Handling, and Research Considerations
PT-141 is supplied as a lyophilized powder and should be stored at -20C for long-term stability. Once reconstituted in bacteriostatic water or an appropriate solvent system, the peptide should be refrigerated at 2 to 8C and used within a reasonable timeframe consistent with standard peptide handling protocols. As with all research peptides, repeated freeze-thaw cycles should be avoided to preserve structural integrity and biological activity. For detailed guidance on peptide reconstitution and solvent selection, researchers can consult our reconstitution research guide.
Purity verification through high-performance liquid chromatography (HPLC) and mass spectrometry is essential for ensuring that experimental results reflect the activity of the intended compound rather than degradation products or synthesis impurities. Researchers sourcing PT-141 should verify that their supplier provides batch-specific certificates of analysis (COAs) documenting purity, identity confirmation by mass spectrometry, and absence of significant impurity peaks. Third-party analytical verification, as discussed in our guide to third-party vs. in-house peptide testing, provides an additional layer of confidence in compound quality.
Maple Research Labs provides PT-141 for research purposes with third-party COA verification and same-day shipping from our Canadian facility.
For research purposes only. Not for human consumption. Not for diagnostic or therapeutic use.
References
Molinoff PB, Shadiack AM, Earle D, Diamond LE, Quon CY. PT-141: a melanocortin agonist for the treatment of sexual dysfunction. Ann N Y Acad Sci. 2003;994:96-102.
Girardet C, Butler AA. Neural melanocortin receptors in obesity and related metabolic disorders. Biochim Biophys Acta. 2014;1842(3):482-494.
Pfaus JG, Shadiack A, Van Soest T, Tse M, Molinoff P. Selective facilitation of sexual solicitation in the female rat by a melanocortin receptor agonist. Proc Natl Acad Sci U S A. 2004;101(27):10201-10204.
Hadley ME, Dorr RT. Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization. Peptides. 2006;27(4):921-930.
Catania A, Gatti S, Colombo G, Lipton JM. Targeting melanocortin receptors as a novel strategy to control inflammation. Pharmacol Rev. 2004;56(1):1-29.